167 related articles for article (PubMed ID: 30393612)
1. LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
Lee RC; Thapa B; John T
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S239-S242. PubMed ID: 30393612
[No Abstract] [Full Text] [Related]
2. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10.
Grieve S; Ding K; Moore J; Finniss M; Ray A; Lees M; Hossain F; Murugesan A; Agar J; Acar C; Taylor J; Shepherd FA; Reiman T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32220948
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Wallerek S; Sørensen JB
Eur Respir Rev; 2015 Jun; 24(136):340-55. PubMed ID: 26028645
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
5. Systemic and targeted therapies for early-stage lung cancer.
Byron E; Pinder-Schenck M
Cancer Control; 2014 Jan; 21(1):21-31. PubMed ID: 24357738
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
Grunnet M; Sorensen JB
Lung Cancer; 2012 May; 76(2):138-43. PubMed ID: 22153832
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of adjuvant chemotherapy in patient with early stages of non-small cell lung cancer depending on proliferation index of tumor].
Kolesnik AP
Lik Sprava; 2014; (1-2):110-7. PubMed ID: 24908971
[TBL] [Abstract][Full Text] [Related]
8. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Eichhorn F; Kriegsmann M; Klotz LV; Kriegsmann K; Muley T; Zgorzelski C; Christopoulos P; Winter H; Eichhorn ME
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922610
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors in resected non-small-cell lung cancer.
Kaira K; Yamamoto N
Expert Opin Med Diagn; 2010 Sep; 4(5):373-81. PubMed ID: 23496196
[TBL] [Abstract][Full Text] [Related]
12. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
Guo NL; Dowlati A; Raese RA; Dong C; Chen G; Beer DG; Shaffer J; Singh S; Bokhary U; Liu L; Howington J; Hensing T; Qian Y
EBioMedicine; 2018 Jun; 32():102-110. PubMed ID: 29861409
[TBL] [Abstract][Full Text] [Related]
13. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.
Ni J; Guo T; Li Y; Yang X; Li Y; Zou L; Chu L; Chu X; Li S; Ye L; Zhang Y; Zhu Z
Transl Lung Cancer Res; 2019 Dec; 8(6):967-978. PubMed ID: 32010575
[TBL] [Abstract][Full Text] [Related]
14. Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
Kang YK; Song YS; Cho S; Jheon S; Lee WW; Kim K; Kim SE
Lung Cancer; 2018 May; 119():1-6. PubMed ID: 29656743
[TBL] [Abstract][Full Text] [Related]
15. Updated Prognostic Factors in Localized NSCLC.
Garinet S; Wang P; Mansuet-Lupo A; Fournel L; Wislez M; Blons H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326552
[TBL] [Abstract][Full Text] [Related]
16. The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study.
Wei S; Shao J; Wang J; Wang G
Ann Transl Med; 2022 Apr; 10(8):457. PubMed ID: 35571436
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy.
Wang M; Li W; Xing X; Zhang D; Lei J; Li G
Oncotarget; 2017 Oct; 8(46):80869-80877. PubMed ID: 29113350
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Brueckl WM; Ficker JH; Zeitler G
BMC Cancer; 2020 Dec; 20(1):1185. PubMed ID: 33272262
[TBL] [Abstract][Full Text] [Related]
20. Adaptive choice of the number of bootstrap samples in large scale multiple testing.
Guo W; Peddada S
Stat Appl Genet Mol Biol; 2008; 7(1):Article13. PubMed ID: 18384266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
